Literature DB >> 9808336

Medical treatment of Parkinson's disease.

S Fahn1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9808336     DOI： 10.1007/pl00007742

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  9 in total

1.  Use of PC12 cells and rat superior cervical ganglion sympathetic neurons as models for neuroprotective assays relevant to Parkinson's disease.

Authors:  Cristina Malagelada Grau; Lloyd A Greene
Journal:  Methods Mol Biol       Date:  2012

2.  Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease.

Authors:  Cristina Malagelada; Zong Hao Jin; Vernice Jackson-Lewis; Serge Przedborski; Lloyd A Greene
Journal:  J Neurosci       Date:  2010-01-20       Impact factor: 6.167

3.  RTP801 is induced in Parkinson's disease and mediates neuron death by inhibiting Akt phosphorylation/activation.

Authors:  Cristina Malagelada; Zong Hao Jin; Lloyd A Greene
Journal:  J Neurosci       Date:  2008-12-31       Impact factor: 6.167

4.  MTOR Pathway-Based Discovery of Genetic Susceptibility to L-DOPA-Induced Dyskinesia in Parkinson's Disease Patients.

Authors:  Núria Martín-Flores; Rubén Fernández-Santiago; Francesa Antonelli; Catalina Cerquera; Verónica Moreno; Maria Josep Martí; Mario Ezquerra; Cristina Malagelada
Journal:  Mol Neurobiol       Date:  2018-07-10       Impact factor: 5.590

5.  SNCA and mTOR Pathway Single Nucleotide Polymorphisms Interact to Modulate the Age at Onset of Parkinson's Disease.

Authors:  Rubén Fernández-Santiago; Núria Martín-Flores; Francesca Antonelli; Catalina Cerquera; Verónica Moreno; Sara Bandres-Ciga; Elisabetta Manduchi; Eduard Tolosa; Andrew B Singleton; Jason H Moore; María-Josep Martí; Mario Ezquerra; Cristina Malagelada
Journal:  Mov Disord       Date:  2019-06-24       Impact factor: 10.338

6.  Dopamine-independent locomotor actions of amphetamines in a novel acute mouse model of Parkinson disease.

Authors:  Tatyana D Sotnikova; Jean-Martin Beaulieu; Larry S Barak; William C Wetsel; Marc G Caron; Raul R Gainetdinov
Journal:  PLoS Biol       Date:  2005-08-02       Impact factor: 8.029

7.  Parkin loss of function contributes to RTP801 elevation and neurodegeneration in Parkinson's disease.

Authors:  J Romaní-Aumedes; M Canal; N Martín-Flores; X Sun; V Pérez-Fernández; S Wewering; R Fernández-Santiago; M Ezquerra; C Pont-Sunyer; A Lafuente; J Alberch; H Luebbert; E Tolosa; O A Levy; L A Greene; C Malagelada
Journal:  Cell Death Dis       Date:  2014-08-07       Impact factor: 8.469

8.  Palmitoyl Serotonin Inhibits L-dopa-induced Abnormal Involuntary Movements in the Mouse Parkinson Model.

Authors:  Hye-Yeon Park; Young-Kyoung Ryu; Jun Go; Eunjung Son; Kyoung-Shim Kim; Mee Ree Kim
Journal:  Exp Neurobiol       Date:  2016-08-08       Impact factor: 3.261

9.  Loss of NEDD4 contributes to RTP801 elevation and neuron toxicity: implications for Parkinson's disease.

Authors:  Mercè Canal; Núria Martín-Flores; Leticia Pérez-Sisqués; Joan Romaní-Aumedes; Bekir Altas; Heng-Ye Man; Hiroshi Kawabe; Jordi Alberch; Cristina Malagelada
Journal:  Oncotarget       Date:  2016-09-13
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.